Cost-effectiveness for metastatic colorectal cancer.

被引：1
|
作者：
Yao, Linli
Han, Jiaqi
She, Longjiang
Ding, Dong
Liao, Mengting
Hu, Huabin
Zeng, Shan
Shen, Liangfang
Huang, Jin
机构：
[1] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15003
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC).
    Lakdawalla, D.
    Penrod, J.
    Maclean, R.
    Humphrey, J. S.
    Seabury, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [32] COST-EFFECTIVENESS OF REGORAFENIB FOR METASTATIC COLORECTAL CANCER IN THE CONTEXT OF THE HEALTHCARE SYSTEM OF KAZAKHSTAN
    Almadiyeva, A.
    Abeuov, A.
    Absattarova, K.
    Sultanov, M.
    VALUE IN HEALTH, 2019, 22 : S480 - S481
  • [33] Cost-effectiveness of regorafenib for pretreated metastatic colorectal cancer patients in the United States
    Seal, Brian S.
    Oezer-Stillman, Ipek
    Whalen, John
    Ambavane, Apoorva
    Yaldo, Avin
    Pawar, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [34] THE COST-EFFECTIVENESS OF CETUXIMAB USE AMONG ELDERLY METASTATIC COLORECTAL CANCER PATIENTS
    Wei, D. B.
    Lin, C. C.
    VALUE IN HEALTH, 2010, 13 (03) : A35 - A35
  • [35] COST-EFFECTIVENESS OF CETUXIMAB FOR LEFT-SIDE METASTATIC COLORECTAL CANCER IN ECUADOR
    Cabezas, M.
    Freire, V
    Salcedo, E.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S31 - S32
  • [36] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB USED IN CHINESE PATIENTS WITH METASTATIC COLORECTAL CANCER
    Zhang, S.
    Ma, A. X.
    Li, H.
    Rascati, K.
    VALUE IN HEALTH, 2020, 23 : S43 - S43
  • [37] Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
    Behl, Ajay S.
    Goddard, Katrina A. B.
    Flottemesch, Thomas J.
    Veenstra, David
    Meenan, Richard T.
    Lin, Jennifer S.
    Maciosek, Michael V.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (23): : 1785 - 1795
  • [38] Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher
    Hall, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
    Carvalho, Adriana Camargo
    Leal, Frederico
    Sasse, Andre Deeke
    PLOS ONE, 2017, 12 (04):
  • [40] Cost-effectiveness of hepatic artery infusion for metastatic colorectal cancer (CALGB 9481)
    Weeks, JC
    Romanus, D
    Herndon, JE
    Schrag, D
    Mayer, RJ
    Kemeny, N
    VALUE IN HEALTH, 2005, 8 (06) : A37 - A37
12345